Accord BioPharma Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, announced that Express Scripts, one of ...

HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...

11/14/2025 Motion to extend the time to file a response from December 1, 2025 to January 15, 2026, submitted to The Clerk. 11/14/2025 Response of Express Scripts, Inc., et al. to motion submitted.

Oregon's Attorney General sues insulin manufacturers and PBMs for $900 million, alleging price inflation and collusion, ...

Our team of savvy editors independently handpicks all recommendations. If you make a purchase through our links, we may earn a commission. Deals and coupons were accurate at the time of publication ...

The room we are in is locked. It is windowless and lit from above by a fluorescent bulb. In the hallway outside—two stories beneath the city of London—attendants in dark suits patrol silently, giving ...